Obesity-related heart failure with a preserved ejection fraction (HFpEF) is an important
phenotype prevalent in the community, especially in people with metabolic disorders (eg …

Among patients with heart failure and a preserved ejection (HFpEF), obesity is associated
with a distinct phenotype that is characterized by adiposity‐driven plasma volume expansion …

Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors reduce the risk of serious heart failure
events in patients with type 2 diabetes, but little is known about mechanisms that might …

Heart failure with preserved ejection fraction (HFpEF) is a major unmet medical need that is
characterized by the presence of multiple cardiovascular and non-cardiovascular …

Obesity and heart failure with preserved ejection fraction (HFpEF) represent two
intermingling epidemics driving perhaps the greatest unmet health problem in …

Heart failure with a preserved ejection fraction (HFpEF) and heart failure with a reduced
ejection fraction (HFrEF) have distinctive pathophysiologies, and thus, therapeutic …

Heart failure (HF) is a widespread public health problem with increasing burdens of
morbidity, mortality, and health care costs. As of 2018, approximately 6.5 million American …

Accumulating evidence points to the existence of an inflammatory‐metabolic phenotype of
heart failure with a preserved ejection fraction (HFpEF), which is characterized by …

Background—Despite the increasing prevalence of heart failure with preserved ejection
fraction (HFpEF) in humans, there are no evidence-based therapies for HFpEF. Clinical …

Background: Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous
syndrome. Phenotyping patients into pathophysiologically homogeneous groups may …